Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts. The company focuses on developing and commercializing novel therapies for life-threatening diseases, particularly those related to antimicrobial resistance (AMR). Paratek utilizes its expertise in biology and tetracycline chemistry to create small molecules derived from the minocycline core structure.

Paratek's product portfolio includes FDA-approved antibiotics such as NUZYRA (omadacycline), which is used to treat community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA (sarecycline), an antibiotic for moderate to severe acne vulgaris. The company serves a diverse range of customers, including adult patients with bacterial infections, adolescents with acne, and various public health sectors, including civilian healthcare and military applications.

In addition to its focus on innovative therapies, Paratek is committed to corporate responsibility and sustainability, integrating environmental, social, and governance principles into its operations. The company aims to address critical global health challenges while fostering a culture that benefits employees, customers, and patients.